ArticleNutrition & diabetes2025
Kefir-derived exopolysaccharide ameliorates hyperglycemic control and beta cell integrity in a rat model of type 2 diabetes mellitus.
Article in Nutrition & diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dairy Bioactive Compounds as Precision Modulators of Gut Microbiota: From Molecular Mechanisms to Personalized Immunometabolic Health.Foods (Basel, Switzerland) · 2026Review
- Probiotics and Postbiotics in Life-Style Disease Management: A Comprehensive Review on the Technologies in the Era of Omics and Artificial Intelligence.Probiotics and antimicrobial proteins · 2026Review
- Kefir Consumption and Health Effects Based on Human Clinical Trials: An Overview of Literature.Healthcare (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveDiabetes mellitus (DM) is a chronic metabolic disorder characterized by elevated blood glucose levels due to insulin deficiency or resistance. While conventional treatments are effective, integrating nutraceuticals that aid in blood sugar control is crucial for patients with low compliance or prediabetes. This study aimed to assess the efficacy of kefir-derived exopolysaccharides (KEPS) in ameliorating type 2 DM in rats induced by streptozotocin (STZ) and a high-fat diet.
resultsEight-week-old male SD rats were fed a high-fat diet for 4 weeks and subsequently administered STZ (35 mg/kg body weight) via intraperitoneal injection to induce type 2 diabetes. Diabetic rats were randomly assigned to three groups: untreated diabetes (mock), diabetic rats + high-dose KEPS (STZ-KEPSH), and diabetic rats + low-dose KEPS (STZ-KEPSL), and treated for an additional 4 weeks. An age-matched SD rat group without STZ induction was used as a control. Our findings demonstrate that high-dose KEPS administration in diabetic rats enhances hepatic glucose uptake and stabilizes blood glucose levels by upregulating GLUT2 protein expression and PI3k phosphorylation in liver cells. KEPS mitigates lipid production, reduces β cell damage, and preserves islet cell integrity, thereby improving insulin sensitivity and alleviating diabetes symptoms. High-dose KEPS treatment also exhibits less renal enlargement and lower kidney-to-body weight ratio than the diabetic group.
conclusionExopolysaccharides derived from kefir show promising potential in managing type 2 diabetes mellitus in rats, suggesting a viable nutraceutical therapy. Further research is needed to validate these findings in human subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.